Superworth

Acumen Pharmaceuticals EPS ABOS

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Sep 30, 2026
−$1.54
Latest quarter, Q3 FY26
−$0.35
Fiscal year 2025
−$2.01

Acumen Pharmaceuticals' earnings per share was −$1.54 over the twelve months to Sep 30, 2026.

In its latest quarter, Q3 FY26, it was −$0.35.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.01n/a
FY2024−$1.71n/a
FY2023−$1.08n/a
FY2022−$1.05n/a
FY2021−$206.65n/a
FY2020−$17.48n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.35n/a−$1.54
Q2 FY26−$0.45n/a−$1.63
Q1 FY26−$0.33n/a−$1.86
Q4 FY25−$0.41n/a−$2.01
Q3 FY25−$0.44n/a−$2.22
Q2 FY25−$0.68n/a−$2.28
Q1 FY25−$0.48n/a−$1.94
Q4 FY24−$0.62n/a−$1.71
Q3 FY24−$0.50n/a−$1.37
Q2 FY24−$0.34n/a−$1.11
Q1 FY24−$0.25n/a−$1.05
Q4 FY23−$0.28n/a−$1.08

Against its peers

Companies in Healthcare nearest Acumen Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ABOSAcumen Pharmaceuticals−$1.54
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Acumen Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.